Table 1.
Treatment Groups and Patient Characteristics in Trials VI and VII
| Pre/perimenopausal (Trial VI) |
Postmenopausal (Trial VII) |
|||
|---|---|---|---|---|
| CMF×3 | CMF×6 | No Initial CMF |
CMF × 3 | |
| Randomized | 725 | 750 | 614 | 598 |
| Treatment Assignment | ||||
| CT×3→RT | 360 | |||
| CT×3→RT→CT×1 at mos 6, 9, 12 | 364 | |||
| CT×6→RT | 375 | |||
| CT×6→RT→CT×1 at months 9, 12, 15 | 375 | |||
| Tamoxifen + RT | 306 | |||
| Tamoxifen + RT→CT×1 mos 9, 12, 15 | 308 | |||
| Tamoxifen+CT×3→RT | 302 | |||
| Tamoxifen+CT×3→RT→CT×1 mos 9, 12, 15 | 296 | |||
| Breast-conserving surgery+RT (analytic cohort) | 213 | 220 | 146 | 139 |
| Age median (range) | 44 (27–56) | 44 (26–56) | 60 (45–76) | 60 (46–76) |
| Age <40 (%) | 51 (24) | 50 (23) | ||
| Age ≥40 (%) | 162 (76) | 170 (77) | ||
| Age <65 (%) | 112 (77) | 108 (78) | ||
| Age ≥65 (%) | 34 (23) | 31 (22) | ||
| ER Negative* (%) | 54 (25) | 64 (29) | 30 (21) | 22 (16) |
| ER Positive (%) | 159 (75) | 156 (71) | 116 (79) | 117 (84) |
| 1–3 Nodes positive (%) | 165 (77) | 164 (77) | 111 (76) | 98 (71) |
| ≥4 Nodes positive (%) | 48 (23) | 56 (25) | 35 (24) | 41 (29) |
*
<10 fmol/mg cytosol protein